SCHEMBL10043849

SCHEMBL10043849

Cc1cc2c(cn1)cc(-c1cc(NC(=O)Nc3ccc(Cl)cc3Cl)ccc1C)c(=O)n2C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
MAPT P10636 9/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
RAB9A P51151 5/20 0.41
NPC1 O15118 4/20 0.41
POLB P06746 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ATM Q13315 1/20 0.40
KDM4E B2RXH2 1/20 0.39
IDH1 O75874 2/20 0.39
FGFR1 P11362 2/20 0.39
SRC P12931 2/20 0.39
SYK P43405 1/20 0.38
HTT P42858 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
AGPAT2 O15120 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043828 0.86 RAB9A (0.48) MAPTRAB9ANPC1POLBSMN1; SMN2
SCHEMBL10043821 0.84 SYK (0.49) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL10043851 0.84 PCTP (0.44) MAPTRAB9ANPC1POLBSMN1; SMN2
SCHEMBL10043835 0.83 HTR2A (0.43) HTR2AHTR2CMAPTKMT2AMEN1
SCHEMBL10043744 0.83 SYK (0.44) RAB9ANPC1SMN1; SMN2FGFR1SRC
SCHEMBL10043833 0.83 RAB9A (0.46) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL10043842 0.83 RAB9A (0.48) HTR2AMAPTKMT2AMEN1RAB9A
SCHEMBL10043846 0.83 KDR (0.49) HTR2AHTR2CSYK
SCHEMBL10043830 0.83 SMARCA2 (0.48) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL10072187 0.81 SYK (0.47) MAPTRAB9ANPC1POLBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC HTR2A 2717/4885HTR2C 2796/4885MAPT 2514/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC HTR2A 2717/4885HTR2C 2796/4885MAPT 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.